GLP-1 drugs shift from obesity treatment to lifestyle market

GLP-1 receptor agonists, initially positioned as obesity medicines for patients, are increasingly marketed as lifestyle drugs for customers, reflecting a commercial pivot by manufacturers. This shift may expand the market but raises regulatory and public-health questions about long-term use and access. The trend is corroborated by industry marketing and prescribing patterns, though its full implications remain uncertain.